Adaptive immune responses to SARS-CoV-2.

Authors:
Forthal D.

Journal:
Adv Drug Deliv Rev

Publication Year: 2021

DOI:
10.1016/j.addr.2021.02.009

PMCID:
PMC7891074

PMID:
33610693

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Adv Drug Deliv Rev

Abbreviation: Adv Drug Deliv Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Drug Therapy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics.
Kang DD; Li H; Dong Y. (2023) - Transparency Score: 3/6
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery.
Han G; Noh D; Lee H and 4 more (2023) - Transparency Score: 3/6
Imaging drug delivery to the lungs: Methods and applications in oncology.
Man F; Tang J; Swedrowska M and 2 more (2022) - Transparency Score: 3/6
In vivo fate and intracellular trafficking of vaccine delivery systems.
Lee J; Kim D; Byun J and 3 more (2022) - Transparency Score: 3/6
Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases.
Aldarondo D; Wayne E. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
16.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025